Gestational trophoblastic disease: Is intensive follow up essential in all women?

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 111, Issue 12, 2004, Pages 1449-1451

  Pisal, Narendra ^a   Tidy, John ^b   Hancock, Barry ^c  

^a WHITTINGTON HOSPITAL   (United Kingdom)

^b JESSOP HOSPITAL FOR WOMEN   (United Kingdom)

^c WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HORMONE URINE LEVEL; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL RECORD; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL ANALYSIS; TROPHOBLASTIC DISEASE; TROPHOBLASTIC TUMOR;

ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CHORIONIC GONADOTROPIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDATIDIFORM MOLE; PREGNANCY; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TIME FACTORS;

EID: 10844275613     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2004.00339.x     Document Type: Article

References (14)

1. Bagshawe KD, Dent J, Webb J. Hydatidiform, mole in England and Wales 1973-1983. Lancet 1986;2:673-677.
2. Tham BWL, Everard JE, Tidy JA, Drew D, Hancock BW. Gestational trophoblastic disease in the Asian population of Northern England and North Wales. Br J Obstet Gynaecol 2003;110(6):555-559.
3. Paradinas FJ. The histological diagnosis of hydatidiform moles. Curr Diagn Pathol 1994;1:24-31.
4. Hancock BW. Differences in management and treatment: a critical appraisal. In: Hancock BW, Newlands ES, Berkowitz RS, editors. Gestational Trophoblastic Disease. London: Chapman & Hall, 1997:211-216.
5. The management of gestational trophoblastic disease. RCOG Clinical Guidelines. London: Royal College of Obstetricians and Gynaecologists, 1999.
6. Smith DB, Holden L, Newlands ES, Bagshawe KD. Correlation between clinical staging (FIGO) and prognostic groups with gestational trophoblastic disease. Br J Obstet Gynaecol 1993;100(2):157-160.
7. Berkowitz RS, Goldstein DP. Presentation and management of molar pregnancy. In: Hancock BW, Newlands ES, Berkowitz RS, editors. Gestational Trophoblastic Disease. London: Chapman & Hall Medical, 1997:127-142.
8. Goto S, Yamada A, Ishizuka T, Tomoda Y. Development of postmolar trophoblastic disease after partial molar pregnancy. Gynecol Oncol 1993;48(2):165-170.
9. Bandy LC, Clarke-Pearson DL, Hammond CB. Malignant potential of gestational trophoblastic disease at the extreme ages of reproductive life. Obstet Gynecol 1984;64(3):395-399.
10. Newlands ES. Investigations and treatment of patients with persistent gestational trophoblastic disease and gestational trophoblastic tumours in the UK. In: Hancock BW, Newlands ES, Berkowitz RS, editors. Gestational Trophoblastic Disease. London: Chapman & Hall Medical, 1997:175-192.
11. Sebire NJ, Fisher RA, Foskett M, Rees H, Seckl MJ, Newlands ES. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. Br J Obstet Gynaecol 2003;110(1):22-26.
12. Seckl MJ, Fisher RA, Salerno G, et al. Choriocarcinoma and partial hydatidiform moles. Lancet 2000;356(9223):36-39.
13. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia. Int J Obstet Gynaecol 2002;77:285-287.
14. Gillespie AM, Kumar S, Hancock BW. Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy. Br J Cancer 2000;82(8):1393-1395.